Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study

the National Birth Defects Prevention Study

Research output: Contribution to journalArticle

Abstract

Background: There are limited data on the relationship between antihypertensive medication use in early pregnancy and risk of birth defects. Methods: Using data from the National Birth Defects Prevention Study, we examined associations between specific antihypertensive medication classes and 28 noncardiac birth defects. We analyzed self-reported data on 17,038 case and 11,477 control pregnancies with estimated delivery dates during 1997–2011. We used multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals, adjusted for maternal age, race/ethnicity, body mass index, parity, pregestational diabetes, and study site, for associations between individual birth defects and antihypertensive medication use during the first trimester of pregnancy. We compared risk among women reporting early pregnancy antihypertensive medication use to normotensive women. Results: Hypertensive women who reported early pregnancy antihypertensive medication use were more likely to be at least 35 years old, non-Hispanic Black, obese, multiparous, and to report pregestational diabetes than normotensive women. Compared to normotensive women, early pregnancy antihypertensive medication use was associated with increased risk of small intestinal atresia (adjusted OR 2.4, 95% CI 1.2–4.7) and anencephaly (adjusted OR 1.9, 95% CI 1.0–3.5). Risk of these defects was not specific to any particular medication class. Conclusions: Maternal antihypertensive medication use was not associated with the majority of birth defects we analyzed, but was associated with an increased risk for some birth defects. Because we cannot entirely rule out confounding by the underlying hypertension and most ORs were based on small numbers, the increased risks observed should be interpreted with caution.

Original languageEnglish (US)
JournalBirth Defects Research
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Antihypertensive Agents
Mothers
Defects
Pregnancy
Odds Ratio
Medical problems
Intestinal Atresia
Anencephaly
Maternal Age
First Pregnancy Trimester
Parity
Logistics
Body Mass Index
Logistic Models
Confidence Intervals
Hypertension

Keywords

  • antihypertensive
  • birth defects
  • hypertension
  • National Birth Defects Prevention Study
  • pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Toxicology
  • Developmental Biology
  • Health, Toxicology and Mutagenesis

Cite this

Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study. / the National Birth Defects Prevention Study.

In: Birth Defects Research, 01.01.2018.

Research output: Contribution to journalArticle

@article{f7e2de7d26b94dc19e65fbdf8403a67b,
title = "Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study",
abstract = "Background: There are limited data on the relationship between antihypertensive medication use in early pregnancy and risk of birth defects. Methods: Using data from the National Birth Defects Prevention Study, we examined associations between specific antihypertensive medication classes and 28 noncardiac birth defects. We analyzed self-reported data on 17,038 case and 11,477 control pregnancies with estimated delivery dates during 1997–2011. We used multivariable logistic regression to estimate odds ratios (ORs) and 95{\%} confidence intervals, adjusted for maternal age, race/ethnicity, body mass index, parity, pregestational diabetes, and study site, for associations between individual birth defects and antihypertensive medication use during the first trimester of pregnancy. We compared risk among women reporting early pregnancy antihypertensive medication use to normotensive women. Results: Hypertensive women who reported early pregnancy antihypertensive medication use were more likely to be at least 35 years old, non-Hispanic Black, obese, multiparous, and to report pregestational diabetes than normotensive women. Compared to normotensive women, early pregnancy antihypertensive medication use was associated with increased risk of small intestinal atresia (adjusted OR 2.4, 95{\%} CI 1.2–4.7) and anencephaly (adjusted OR 1.9, 95{\%} CI 1.0–3.5). Risk of these defects was not specific to any particular medication class. Conclusions: Maternal antihypertensive medication use was not associated with the majority of birth defects we analyzed, but was associated with an increased risk for some birth defects. Because we cannot entirely rule out confounding by the underlying hypertension and most ORs were based on small numbers, the increased risks observed should be interpreted with caution.",
keywords = "antihypertensive, birth defects, hypertension, National Birth Defects Prevention Study, pregnancy",
author = "{the National Birth Defects Prevention Study} and Fisher, {Sarah C.} and {Van Zutphen}, {Alissa R.} and Werler, {Martha M.} and Romitti, {Paul A.} and Cunniff, {Christopher M} and Browne, {Marilyn L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/bdr2.1372",
language = "English (US)",
journal = "Birth Defects Research",
issn = "2472-1727",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study

AU - the National Birth Defects Prevention Study

AU - Fisher, Sarah C.

AU - Van Zutphen, Alissa R.

AU - Werler, Martha M.

AU - Romitti, Paul A.

AU - Cunniff, Christopher M

AU - Browne, Marilyn L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: There are limited data on the relationship between antihypertensive medication use in early pregnancy and risk of birth defects. Methods: Using data from the National Birth Defects Prevention Study, we examined associations between specific antihypertensive medication classes and 28 noncardiac birth defects. We analyzed self-reported data on 17,038 case and 11,477 control pregnancies with estimated delivery dates during 1997–2011. We used multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals, adjusted for maternal age, race/ethnicity, body mass index, parity, pregestational diabetes, and study site, for associations between individual birth defects and antihypertensive medication use during the first trimester of pregnancy. We compared risk among women reporting early pregnancy antihypertensive medication use to normotensive women. Results: Hypertensive women who reported early pregnancy antihypertensive medication use were more likely to be at least 35 years old, non-Hispanic Black, obese, multiparous, and to report pregestational diabetes than normotensive women. Compared to normotensive women, early pregnancy antihypertensive medication use was associated with increased risk of small intestinal atresia (adjusted OR 2.4, 95% CI 1.2–4.7) and anencephaly (adjusted OR 1.9, 95% CI 1.0–3.5). Risk of these defects was not specific to any particular medication class. Conclusions: Maternal antihypertensive medication use was not associated with the majority of birth defects we analyzed, but was associated with an increased risk for some birth defects. Because we cannot entirely rule out confounding by the underlying hypertension and most ORs were based on small numbers, the increased risks observed should be interpreted with caution.

AB - Background: There are limited data on the relationship between antihypertensive medication use in early pregnancy and risk of birth defects. Methods: Using data from the National Birth Defects Prevention Study, we examined associations between specific antihypertensive medication classes and 28 noncardiac birth defects. We analyzed self-reported data on 17,038 case and 11,477 control pregnancies with estimated delivery dates during 1997–2011. We used multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals, adjusted for maternal age, race/ethnicity, body mass index, parity, pregestational diabetes, and study site, for associations between individual birth defects and antihypertensive medication use during the first trimester of pregnancy. We compared risk among women reporting early pregnancy antihypertensive medication use to normotensive women. Results: Hypertensive women who reported early pregnancy antihypertensive medication use were more likely to be at least 35 years old, non-Hispanic Black, obese, multiparous, and to report pregestational diabetes than normotensive women. Compared to normotensive women, early pregnancy antihypertensive medication use was associated with increased risk of small intestinal atresia (adjusted OR 2.4, 95% CI 1.2–4.7) and anencephaly (adjusted OR 1.9, 95% CI 1.0–3.5). Risk of these defects was not specific to any particular medication class. Conclusions: Maternal antihypertensive medication use was not associated with the majority of birth defects we analyzed, but was associated with an increased risk for some birth defects. Because we cannot entirely rule out confounding by the underlying hypertension and most ORs were based on small numbers, the increased risks observed should be interpreted with caution.

KW - antihypertensive

KW - birth defects

KW - hypertension

KW - National Birth Defects Prevention Study

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85053048016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053048016&partnerID=8YFLogxK

U2 - 10.1002/bdr2.1372

DO - 10.1002/bdr2.1372

M3 - Article

C2 - 30260586

AN - SCOPUS:85053048016

JO - Birth Defects Research

JF - Birth Defects Research

SN - 2472-1727

ER -